Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 shows clinical signal disease relevance led by clear cell renal carcinoma. 1 more disease program remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt O14638. Start with clear cell renal carcinoma, then reuse UniProt O14638 as the stable protein anchor across project notes and exports.
Start with clear cell renal carcinoma, then reuse UniProt O14638 as the stable protein anchor across project notes and exports.
Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 shows clinical signal disease relevance led by clear cell renal carcinoma. 1 more disease program remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with clear cell renal carcinoma because it currently carries clinical signal support. Linked drugs include AGS-16C3F. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyEctonucleotide pyrophosphatase/phosphodiesterase family member 3
Review this target as Ectonucleotide pyrophosphatase/phosphodiesterase family member 3, mapped to UniProt O14638. Sequence length is 875 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 as ChEMBL target CHEMBL5580, mapped to UniProt O14638. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 is the right protein anchor across sources, using UniProt O14638 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why clear cell renal carcinoma is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | O14638 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 |
| UniProt Accession | O14638 |
| Component Type | Protein |
| Sequence Length | 875 aa |
Ectonucleotide pyrophosphatase/phosphodiesterase family member 3
Review this target as Ectonucleotide pyrophosphatase/phosphodiesterase family member 3, mapped to UniProt O14638. Sequence length is 875 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 shows clinical signal disease relevance led by clear cell renal carcinoma. 1 more disease program remain visible in the same review block.
Start review with clear cell renal carcinoma because it currently carries clinical signal support. Linked drugs include AGS-16C3F. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL5566114 | 10.05 | IC50 | 0.09 | Preclinical |
| CHEMBL265502 | 7.4 | Ki | 40.0 | Clinical |
| CHEMBL2336905 | 7.27 | Ki | 53.7 | Preclinical |
| CHEMBL1485038 | 6.93 | Ki | 117.0 | Preclinical |
| CHEMBL4753995 | 6.82 | IC50 | 150.0 | Preclinical |
| CHEMBL4791706 | 6.77 | IC50 | 170.0 | Preclinical |
| CHEMBL4859945 | 6.68 | IC50 | 210.0 | Preclinical |
| CHEMBL4573280 | 6.67 | IC50 | 214.0 | Preclinical |
| CHEMBL4280275 | 6.64 | IC50 | 230.0 | Preclinical |
| CHEMBL4540180 | 6.64 | IC50 | 230.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 29 | 82 | 5.5 |
| single protein format | 15 | 5 | 6.3 |
| assay format | 5 | 32 | 5.8 |
| cell membrane format | 2 | 10 | 5.8 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 5 | 0 | — |
| cell-based format | 2 | 0 | — |